- Home
- PWR vs IQV Comparison
PWR vs IQV Comparison
Compare PWR & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWR
- IQV
- Stock Information
- Founded
- PWR 1997
- IQV 1982
- Country
- PWR United States
- IQV United States
- Employees
- PWR N/A
- IQV N/A
- Industry
- PWR Engineering & Construction
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- PWR Industrials
- IQV Health Care
- Exchange
- PWR Nasdaq
- IQV Nasdaq
- Market Cap
- PWR 45.7B
- IQV 38.1B
- IPO Year
- PWR 1998
- IQV 2013
- Fundamental
- Price
- PWR $341.48
- IQV $194.46
- Analyst Decision
- PWR Strong Buy
- IQV Buy
- Analyst Count
- PWR 16
- IQV 16
- Target Price
- PWR $314.36
- IQV $256.60
- AVG Volume (30 Days)
- PWR 932.8K
- IQV 2.2M
- Earning Date
- PWR 10-31-2024
- IQV 10-31-2024
- Dividend Yield
- PWR 0.11%
- IQV N/A
- EPS Growth
- PWR 15.31
- IQV 27.98
- EPS
- PWR 5.41
- IQV 7.62
- Revenue
- PWR $22,903,321,000.00
- IQV $15,315,000,000.00
- Revenue This Year
- PWR $14.71
- IQV $3.68
- Revenue Next Year
- PWR $12.37
- IQV $4.89
- P/E Ratio
- PWR $61.44
- IQV $25.35
- Revenue Growth
- PWR 17.36
- IQV 3.10
- 52 Week Low
- PWR $180.97
- IQV $187.62
- 52 Week High
- PWR $335.00
- IQV $261.73
- Technical
- Relative Strength Index (RSI)
- PWR 70.24
- IQV 30.04
- Support Level
- PWR $320.00
- IQV $187.62
- Resistance Level
- PWR $333.81
- IQV $194.48
- Average True Range (ATR)
- PWR 8.49
- IQV 7.50
- MACD
- PWR 0.85
- IQV -1.67
- Stochastic Oscillator
- PWR 99.14
- IQV 14.34
About PWR Quanta Services Inc.
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under three reportable segments: electric power, renewables infrastructure, and underground utility and infrastructure.
About IQV IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.